Introduction
Nosocomial infections with multiresistant Enterococcus faecium are a growing problem worldwide. Currently, enterococci, represent the third leading cause of nosocomial bloodstream infections in the USA. 1 Patients developing infections with E. faecium are almost invariably hospitalized and severely immune debilitated, suffering from different co-morbid diseases. Knowledge of host defence mechanisms contributing to an effective immune response to E. faecium is limited. Such knowledge is necessary in light of the growing impact of E. faecium on health care and the relative lack of antibiotics that are active against this multiresistant bacterium.
Tissue injury, infection and infl ammation are associated with a non-specifi c systemic response, the so-called acute-phase response (APR). 2 This response to tissue damage is often seen in patients suffering from a variety of medical conditions such as trauma, major surgery, burn, tissue infarction, chronic illness or advanced cancer. During the APR, levels of many plasma proteins are increased, e.g. proteinase inhibitors, clotting and complements proteins, C-reactive protein, serum amyloid A and, in mice, serum amyloid P (SAP). The APR has generally been regarded as a benefi cial response for the host, e.g.
facilitating the elimination of micro-organisms and the repair of injured tissue. In line with this assumption, mice with a pre-existing APR demonstrated survival benefi ts in models of overwhelming sepsis induced by high-dose administration of Escherichia coli or Klebsiella pneumoniae. 3, 4 However, our laboratory recently provided evidence that the APR impairs host defence in pneumonia caused by the clinically relevant nosocomial pathogens Acinetobacter baumannii 5 and Pseudomonas aeruginosa. 6 Clinical studies have further supported the possibility that the APR may have a negative impact on the immune response to infection; i.e. patients with an APR before going into surgery had more and worse infection outcomes. 7, 8 Considering that patients infected with E. faecium virtually always have underlying diseases that are accompanied by an APR, we here investigated the effect of a preexisting APR, induced by two well-established models for this response, subcutaneous injections of turpentine 5, 6, 9 or casein, 3 on host defence against E. faecium peritonitis.
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Mice
Specifi c pathogen-free 10-wk-old female C57BL/6 mice were purchased from Harlan 
Experimental designs
To induce an APR, mice were subcutaneously injected either with 100 μl turpentine (Sigma, St Louis, MO) in both hind limbs, or 0.5 ml of 10% (w/v) casein (Sigma) in 0.05 M NaHCO 3 on the back, as described previously. 3, 5, 6, 9 Control mice received subcutaneous saline or 0.05 M NaHCO 3 buffer, respectively. Twenty-four hours later, mice were intraperitoneally injected with E. faecium according to methods described previously. 11 Bacteria were cultured in Todd Hewitt broth (Difco) at 37˚C, harvested at mid-log phase, and washed twice in sterile saline to clear the bacteria of medium. Bacteria were resuspended in sterile isotonic saline and mice were injected intraperitoneally with approximately 10 8 colony-forming units (CFU) of E. faecium in 200 μl sterile isotonic saline. This bacterial dose is gradually cleared by normal wild-type mice and is not associated with lethality.
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We specifi cally selected this dose because it allows for investigating the impact of an APR on antibacterial defence mechanisms; higher doses are less clinically relevant because these result in early lethality caused by a toxic effect of the extremely high bacterial load administered. 11 The inoculum was plated immediately after inoculation on sheep blood agar plates to determine viable counts. Experiments with turpentine-induced APR were performed on two separate occasions. In the fi rst experiment mice were injected with a fi nal inoculum of 8x10 7 CFU of E. faecium and killed after 2, 6 and 24 hours. In the second experiment the fi nal inoculum was 9x10 7 CFU and mice were killed after 2, 3 and 7 days.
Casein-injected mice were inoculated intraperitoneally with 9x10 7 CFU of E. faecium and killed 2 or 48 h after infection.
Collection of samples
Mice were anesthetized by inhalation of isofl urane (Abbot, Laboratories Ltd., Kent, UK)/ 0 2 (2%/ 2 litre) and a peritoneal lavage was performed with 5 ml sterile PBS using a 18-gauge needle; peritoneal lavage fl uid was collected in sterile polypropylene tubes (Plastipack; Beckton-Dickinson, Mountain View, CA). After collection of peritoneal fl uid, blood was drawn by cardiac puncture, transferred to heparin-gel vacutainer tubes and immediately placed on ice. Next, the abdomen was opened and the liver and lungs were harvested.
Determination of bacterial outgrowth
The number of E. faecium CFU was determined in peritoneal lavage fl uid, blood, liver and lung homogenates. To correct for the differences in organ weight, four times the weight (in milligrams) in microliters of sterile saline was added. The organs were homogenized at 4°C with a tissue homogenizer (Biospect Products, Bartlesville, UK). Next, serial 10-fold dilutions were made of each sample of the homogenates, peritoneal lavage fl uid, and blood in sterile saline and 50 μl of each dilution was plated onto blood agar plates.
The plates were incubated at 37°C under 5% CO 2 , and CFU were counted after 20 h and corrected for the dilution factor.
Cell counts and differentials
Erythrocytes were lysed with ice-cold isotonic NH 4 Assays SAP was measured by a sandwich ELISA, as described previously. 9 In short, sheep antimouse SAP was used as coating antibody, and rabbit anti-mouse SAP as detecting antibody (both Calbiochem-Novabiochem International, San Diego, CA), after which an alkaline phosphatase-conjugated anti-rabbit antibody (Sigma Chemical Co., St Louis, MO) was added. The assay was developed using p-nitrohpenylphosphate; absorption was measured at 405 nm. Complement 3 (C3) was detected by sandwich ELISA as described elsewhere, 9 using goat anti-mouse C3 (ICN, Costa Mesa, CA) as coating antibody, and goat anti-mouse C3c (Nordic, Tilburg, the Netherlands) as detecting antibody. The assay was developed using tetramethyl benzidine and measured at 450 nm. In both ELISAs a 
Statistical analysis
All data are expressed as mean ± SEM. Serial data were analyzed by two-way analysis of variance (ANOVA) followed by a post hoc Bonferroni test. Two group comparisons were performed by Mann-Whitney U test. For all analyses GraphPad Prism version 4 (GraphPad Software, San Diego, CA) was used. A p-value < 0.05 was considered statistically signifi cant.
Results
The turpentine-induced APR strongly impairs bacterial clearance
To determine the effect of a pre-existing APR on host defence against E. faecium peritonitis, mice were infected 24 h after subcutaneous administration of turpentine or saline. As expected, 5, 6, 9 administration of turpentine elicited an APR refl ected by marked elevations of the plasma concentrations of IL-6 and the major acute-phase proteins SAP and C3, 24 h after injection (Fig. 1 , all p < 0.01 versus saline controls). Importantly, a pre-existing APR strongly impaired the clearance of E. faecium after intraperitoneal infection (Fig. 2) . Indeed, whereas mice injected with saline 24 h before infection demonstrated a rapid decline in bacterial loads in all body compartments examined, mice with a preexisting APR had approximately 2 log more E. faecium at the primary site of infection (peritoneal fl uid) up to 7 days after infection ( Fig. 2A) . In addition, in the presence of a pre-existing APR, blood cultures remained positive for at least 3 days, while control mice were no longer bacteremic after 1 day (Fig. 2B) . Differences in bacterial loads in livers more or less followed the pathogen burdens in peritoneal fl uid (Fig. 2C ), whereas differences in lungs were even more profound between groups (Fig. 2D) . injected and saline-injected mice at this time point (Fig. 3B) . In mice without a preexisting APR, intraperitoneal administration of E. faecium resulted in an increase in peripheral blood neutrophil counts within the fi rst 2 h after infection, accompanied by a strong and brisk infl ux of neutrophils into their peritoneal cavity. Remarkably, mice with a turpentine-induced APR displayed a reduced and delayed capacity to mount a peripheral neutrophilia upon intraperitoneal infection with E. faecium; in these animals neutrophil counts in blood only started to increase 2 days after infection (Fig. 3A , p < 0.001 vs salineinjected mice). Even more strikingly, turpentine-injected mice had a strongly diminished infl ux of neutrophils into their peritoneal fl uid after infection with E. faecium (Fig. 3B , p < 0.001). Even though circulating neutrophils were increased after 2 days in these mice, a substantial peritoneal neutrophil infl ux was not observed, although high bacterial loads
were found for at least 3 days after infection. Since CXC chemokines are important for the recruitment of neutrophils to sites of infection and infl ammation, 12 we measured the concentrations of KC and MIP-2 in peritoneal fl uid at various time points after infection with E. faecium. At 2 and 6 h post-infection, the local levels of both chemokines were higher in mice with a turpentine-induced APR (Fig. 3C and 3D ). At later time points peritoneal levels of KC and MIP-2 were undetectable in both groups (data not shown). P-values in the fi gures represent the overall difference between groups; asterisks indicate differences between groups at one time point. *, p<0.05; ***, p<0.001.
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Effect of the turpentine-induced APR on local and systemic cytokine release
The turpentine-induced APR did not infl uence cytokine or chemokine concentrations before infection with E. faecium, besides the increased plasma IL-6 levels listed above (Fig. 1A) . To obtain insight in the effect of a pre-existing APR on cytokine release during E. faecium peritonitis, we measured the concentrations of TNF-α, IL-6, IL-10 and MCP-1 in peritoneal fl uid and plasma at 2 and 6 h and 1, 2 and 7 days after infection. At 2 h post-infection TNF-α, IL-6 and MCP-1 concentrations were lower in peritoneal fl uid of turpentine-injected mice (p < 0.05 vs saline-injected mice), whereas IL-10 levels were similarly low in both groups (Table I ). In plasma, besides an increased level of IL-6 in turpentine-injected mice, no differences in cytokine responses were measured (Table I) .
At later time points post-infection, TNF-α, IL-10 and MCP-1 were low or undetectable in all mice. Plasma IL-6 levels were low but higher in turpentine-injected mice throughout the entire experiment (data not shown). Mice were inoculated i.p. with 10 8 CFU E. faecium 1 day after subcutaneous turpentine or saline injections. Data are mean ± SEM, n = 8 mice/group. *, p<0.05 compared to saline-injected mice.
Casein-induced APR impairs bacterial clearance
Having established that mice with a pre-existing APR induced by subcutaneous injection of turpentine displayed a diminished host defence against E. faecium peritonitis, we next determined whether an APR induced by casein, another well-established model of induced APR, 3 infl uenced the course of this infection in a similar way. Based on the studies using turpentine to induce an APR, we chose to kill the mice 2 or 48 h after infection with E. faecium, considering that these time points were most suitable to study the host infl ammatory response (2 h) and the impact on bacterial clearance (48 h). As expected, of the infection, almost 1 log more bacteria were cultured from the primary site of the infection (peritoneal cavity) of mice injected with casein (Fig. 5A , p < 0.001 vs NaHCO3 controls). Forty-eight hours after the start of the infection higher loads of E. faecium were cultured from all tested organs, i.e. peritoneal lavage fl uid, blood, liver and lungs (Fig. 5) . The most striking difference between casein-injected and control mice was found in blood at this time point: whereas all control mice had cleared E. faecium from their circulation, 7 out of 8 casein-injected mice were bacteremic.
Casein administration was associated with a small but statistically signifi cant decrease in peripheral blood neutrophil counts 24 h post-injection (i.e. directly before infection with E. faecium; Fig. 6A , p<0.05); in peritoneal fl uid such an effect of casein on neutrophil numbers was not observed (Fig. 6B) . Two hours after the infection casein-injected mice were less capable of mounting a neutrophilic response in the circulation (Fig.   6A p<0.01), while they tended to recruit fewer neutrophils into their peritoneal cavity (Fig. 6B, p=0.065) . At 48 h after infection, neutrophil counts did not differ between groups in either blood or peritoneal fl uid. Two hours after E. faecium infection cytokine and chemokine levels did not differ between casein-injected and control mice, except for lower peritoneal IL-6 levels in casein-injected mice (377 ± 75 vs 766 ± 107 pg/ml in control mice, p<0.05; other cytokines not shown). Forty-eight hours after the start of the infection all cytokine and chemokine levels were low or below the detection limit (data not shown). 
Discussion
Infections with multiresistant nosocomial pathogens like E. faecium are almost exclusively found in immunocompromised patients. Many patients who are vulnerable to E. faecium infection demonstrate an APR as a consequence of their underlying disease, for example after major trauma, surgery or burns. 13, 14 Indeed, in one study 74 of 158 (48%) patients with enterococcal bacteremia had undergone recent major surgery or had sustained fullthickness burns or multiple traumatic injuries. 15 Increasing evidence exists that the APR may render patients more susceptible to infections. 5, 6, 16 As a follow-up of our previous studies on the effect of the sterile APR on pulmonary antibacterial host defence in mice, 5, 6 we here studied the effect of this state on host defence in the peritoneal cavity.
Acute-phase response impairs peritoneal host defence By using two well-established murine models for a sterile APR we show that mice with a pre-existing APR are less capable of clearing E. faecium from the primary site of infection (i.e. the peritoneal cavity) and in addition remain bacteremic for several days, whereas control mice had lower bacterial loads in peritoneal fl uid and cleared E. faecium from their circulation within 1 day. These data clearly indicate that a pre-existing APR impairs host defence against E. faecium peritonitis.
To obtain insight into the impact of the APR on the innate immune response to E. faecium peritonitis we used two different models. Both the turpentine-induced and the caseininduced APR was associated with a reduced capacity to mount a rapid neutrophilic suggesting that their blood neutrophils are less responsive to these chemokines. The current data are in line with earlier investigations from our laboratory demonstrating that the turpentine-induced APR is associated with a reduced neutrophil recruitment to the lungs during pneumonia caused by either Pseudomonas or Acinetobacter. 5, 6 Acute injury or trauma is associated with a reduced capacity of immune cells to release proinfl ammatory cytokines upon stimulation with bacterial agonists. 16, 17 We here show that the peritoneal concentrations of TNF-α, IL-6 and MCP-1 were reduced in mice with a turpentine-induced APR after infection with E. faecium peritonitis. Similarly, the APR elicited by turpentine injection was accompanied by a diminished capacity to release cytokines in the pulmonary compartment during bacterial pneumonia. 5, 6 The caseininduced APR only resulted in lower peritoneal IL-6 levels. In this respect it should be noted that casein elicited a less strong APR than turpentine, as indicated by SAP and C3
concentrations. Together with the less profound effects of the casein-induced APR on neutrophil responses, these data suggest that in our studies the reduced cytokine and neutrophil responses are proportional to the extent of the APR.
The effects of a sterile APR on host defence against infection in vivo has been investigated in several other studies. [3] [4] [5] [6] Hochepied et al. 4 demonstrated that turpentine injections protected mice against a lethal intraperitoneal challenge with K. pneumoniae, with reduced systemic bacterial counts. In another lethal model, caused by E. coli peritonitis, fewer bacteria were cultured when the APR was induced by subcutaneous casein injection before the infection. 3 Additionally, these authors found improved survival when casein-treated mice were infected intraperitoneally or intramuscularly with Streptococcus pyogenes. Both studies used very high bacterial challenges that resulted in overwhelming sepsis that was rapidly fatal in normal mice. In fulminant sepsis models inhibition of infl ammation may improve outcome. In accordance, both turpentine and α1-acidglycoprotein (a major APP) protected mice against lethal challenges of LPS and TNF-α. 18 . In our previous studies we investigated respiratory tract infections by the nosocomial pathogens A. baumannii 5 and P. aeruginosa 6 at infectious doses that were not lethal in previously healthy mice. In these settings, the attenuated local proinfl ammatory reaction hampered the normally active innate mechanisms in the lung. Similarly, in the model used here E. faecium is rapidly cleared by the healthy host, resembling the clinical scenario where previously healthy humans are unlikely to develop enterococcal infection. As such, the model is suitable to investigate mechanisms involved in the increased susceptibility of hospitalized patients to this opportunistic pathogen. Our current data clearly suggest that an APR is one underlying condition contributing to impaired defence against E. faecium. The clinical importance of a pre-existing APR and the vulnerability for nosocomial infections is supported by a study in which patients who had an APR before surgery were at increased risk of developing infectious complications postoperatively. 7 The discrepancy between our current fi nding that a pre-existing APR impairs host defence against E. faecium peritonitis and an earlier report demonstrating benefi cial effects of an APR in other infection models 3 may be related to the characteristic of bacterial species and/or infection doses used.
Severe E. faecium infections are almost exclusively seen in severely immunocompromised patients; many of those patients display an APR. Here we sought to determine whether and, if so, to what extent an existing APR (i.e. in the absence of other predisposing factors)
contributes to an enhanced susceptibility to E. faecium infection. We have demonstrated that mice treated with either turpentine or casein to induce an APR are less capable of clearing E. faecium peritonitis, resulting in persistent bacteremia. Together with our earlier studies on the impact of the APR on pulmonary host defence, these data suggest that the APR that accompanies critical illness renders the host vulnerable to infection by common nosocomial pathogens.
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